Psychedelic drug users had less psychological distress and more social support during pandemic lockdowns, according to a recent Tilburg University survey.
Users were more likely to spend time outdoors, maintain healthy diets, meditate, play music, and do yoga. Non-users spent more time watching TV and following COVID news.
In an upcoming clinical trial, agarikon and turkey tail mushrooms will be given to covid-positive patients with mild symptoms. Researchers hope that the mushrooms’ antiviral and immune-boosting properties will prevent symptoms from worsening.
In a separate trial, the same blend of mushrooms will be given to subjects while getting vaccinated to see if it can boost antibody levels.
MindMed (MNMD) launched a study to investigate the effects of microdosing LSD in the morning versus the evening.
Researchers will use digital devices and software to track:
Tennessee-based ketamine company Revitalist (CALM) announced that it’s developing a mental health clinic in the Metaverse 🤯
Patients will be able to attend VR therapy sessions, pay with cryptocurrency, and earn NFTs as part of a rewards program.
To keep up with the growing demand for psychedelic research, the DEA is yet again increasing the legal production quotas for certain Schedule I substances!
The original proposal for psilocybin was just 50 grams, which increased to 1,500 grams in September. The final quota is now 6,000 grams – a total increase of 11,900%!
Production of both MDMA and DMT increased 6,300% from 50 grams to 3,200 grams.
COMPASS Pathways’ (CMPS) stock dropped nearly 30% after announcing mixed study findings and Q3 financial results on Monday.
The company conducted a trial on 233 patients to determine the best psilocybin dose for treatment-resistant depression (TRD).
All three groups showed improvements the day after receiving the dose. The group with the largest dose had the best results, with 36.7% of patients showing at least a 50% decrease in depression scores and 29.1% in remission at week 3. A quarter of the patients showed sustained improvements until week 12.
Unfortunately, 12 patients experienced serious adverse events such as suicidal ideation or self harm, but these behaviours are common in patients with TRD.
The company is preparing for a larger trial beginning next year.
COMPASS also announced that it lost $15.8 million or $0.38 per share in Q3, an improvement compared to its $1.30 loss per share in Q3 of last year.
TripSitter Clinic Corp. now offers at-home ketamine therapy in 10 states!
The company, which is part of Origin Therapeutics’ portfolio, expanded its services to eight new states: Arizona, Colorado, Michigan, Washington, Florida, New York, Ohio, and Virginia, in addition to California and Illinois.
Patients can receive a prescription for oral ketamine after a virtual consultation a physician. They can then take the medication at home with virtual guidance, followed by therapy sessions.
Another company, My Ketamine Home, offers similar services in Texas, Florida, and California.
A little bit of weed could make your trip more spiritual and less scary.
A survey of 321 people suggests that using cannabis while on psychedelics increases the odds of mystical experiences, ego deaths, and intense visuals. These factors are all associated with more spiritual and meaningful experiences!
The data also showed that low doses of cannabis reduced the chances of bad trip, whereas high doses increased feelings of fear and insanity.
Researchers have known for years that ketamine can reduce depression symptoms and suicidal ideation in as little as 24 hours, but a recent study helps us understand why it’s so beneficial.
The study showed that a single dose of ketamine rapidly improved cognitive function, problem-solving abilities, and distorted thinking in suicidal patients.
“Being able to think more clearly can make someone feel less suicidal,” explains Ravi. N. Shah, MD, one of the researchers.
Ketamine was more effective than Midazolam, a benzodiazepine used as a sedative for surgeries. After the dose, suicidal ideation was diminished for up to 6 weeks.
When psilocybin is consumed, it’s metabolized into psilocin, which is the compound that produces most or all of the psychedelic effects. Will the experience change if is psilocin is administered directly?
Filament Health (FH) just received FDA-approval for a first-of-its kind study that will reveal the answer.
The phase I trial at the University of California San Francisco will compare the effects psilocybin and psilocin in 20 healthy patients. Psilocybin will be administered orally, whereas psilocin will be administered both orally and sublingually, meaning it will be absorbed through tissues under the tongue.
Researchers predict that direct psilocin could result in faster onset times, greater consistency and bioavailability, and fewer side effects.
